1
|
Aizman L, Van Den Anker J, Tender J,
Krishnan A and Kirkorian AY: Special management considerations for
propranolol use in breastfed infants of mothers taking
antihypertensives. Pediatr Dermatol. 37:537–540. 2020.PubMed/NCBI View Article : Google Scholar
|
2
|
Munden A, Butschek R, Tom WL, Marshall JS,
Poeltler DM, Krohne SE, Alió AB, Ritter M, Friedlander DF,
Catanzarite V, et al: Prospective study of infantile haemangiomas:
Incidence, clinical characteristics and association with placental
anomalies. Br J Dermatol. 170:907–913. 2014.PubMed/NCBI View Article : Google Scholar
|
3
|
Maguiness SM: Vascular tumors and
malformations in children, introduction. Semin Cutan Med Surg.
35(107)2016.PubMed/NCBI View Article : Google Scholar
|
4
|
Howard MA, Olitsky SE, Rychwalski P and
Mungan N: Management of periocular infantile hemangioma. J Pediatr
Ophthalmol Strabismus. 56:344–346. 2019.PubMed/NCBI View Article : Google Scholar
|
5
|
Léauté-Labrèze C, Harper JI and Hoeger PH:
Infantile haemangioma. Lancet. 390:85–94. 2017.PubMed/NCBI View Article : Google Scholar
|
6
|
Yuzuriha S, Nagai F and Noguchi M: How to
manage disfiguring scars in involuted infantile hemangioma. Adv
Wound Care (New Rochelle). 8:221–229. 2019.PubMed/NCBI View Article : Google Scholar
|
7
|
Hochman M: The role of surgery in the
management of infantile hemangiomas: What is the best timing?
Otolaryngol Clin North Am. 51:119–123. 2018.PubMed/NCBI View Article : Google Scholar
|
8
|
Zhang L, Wu HW, Yuan W and Zheng JW:
Propranolol therapy for infantile hemangioma: Our experience. Drug
Des Devel Ther. 11:1401–1408. 2017.PubMed/NCBI View Article : Google Scholar
|
9
|
Chen ZY, Wang QN, Zhu YH, Zhou LY, Xu T,
He ZY and Yang Y: Progress in the treatment of infantile
hemangioma. Ann Transl Med. 7(692)2019.PubMed/NCBI View Article : Google Scholar
|
10
|
Chinnadurai S, Sathe NA and Surawicz T:
Laser treatment of infantile hemangioma: A systematic review.
Lasers Surg Med. 48:221–233. 2016.PubMed/NCBI View Article : Google Scholar
|
11
|
Leone F, Benanti E, Marchesi A, Marcelli
S, Gazzola R and Vaienti L: Surgical excision of infantile
hemangiomas: A technical refinement to prevent bleeding
complications. J Pediatr Med Chir. 36(7)2014.PubMed/NCBI View Article : Google Scholar
|
12
|
Kagami S, Kuwano Y, Shibata S, Uwajima Y,
Yamada D, Miyamoto A, Miyagawa T, Araki M, Takahashi K, Isomura S,
et al: Propranolol is more effective than pulsed dye laser and
cryosurgery for infantile hemangiomas. Eur J Pediatr.
172:1521–1526. 2013.PubMed/NCBI View Article : Google Scholar
|
13
|
Satterfield KR and Chambers CB: Current
treatment and management of infantile hemangiomas. Surv Ophthalmol.
64:608–618. 2019.PubMed/NCBI View Article : Google Scholar
|
14
|
Techasatian L and Phukam N: Treatment
modalities and outcomes of infantile hemangiomas at srinagarind
hospital. J Med Assoc Thai. 99 (Suppl 5):S74–S80. 2016.PubMed/NCBI
|
15
|
Qiu Y, Lin X, Ma G, Chang L, Jin Y, Chen H
and Hu X: Eighteen cases of soft tissue atrophy after intralesional
bleomycin a5 injections for the treatment of infantile hemangiomas:
A long-term follow-up. Pediatr Dermatol. 32:188–191.
2015.PubMed/NCBI View Article : Google Scholar
|
16
|
White CW, Sondheimer HM, Crouch EC, Wilson
H and Fan LL: Treatment of pulmonary hemangiomatosis with
recombinant interferon alfa-2a. N Engl J Med. 320:1197–1200.
1989.PubMed/NCBI View Article : Google Scholar
|
17
|
Chai Y, Zhou Z, Song J, Lv R, Xu G, Bi J,
Li X, Li Z and Huo R: Safety of ntralesional injection of
lauromacrogol combined with triamcinolone for infantile
hemangiomas. J Dermatol. 46:770–776. 2019.PubMed/NCBI View Article : Google Scholar
|
18
|
Sinha S and Lloyd MS: Propranolol for
surgeons in the treatment of infantile hemangiomas. J Craniofac
Surg. 31:134–137. 2020.PubMed/NCBI View Article : Google Scholar
|
19
|
Wasserman JD, Mahant S, Carcao M, Perlman
K and Pope E: Vincristine for successful treatment of
steroid-dependent infantile hemangiomas. Pediatrics.
135:e1501–e1505. 2015.PubMed/NCBI View Article : Google Scholar
|
20
|
Düzenli Kar Y, Özdemir ZC, Acu B and Bör
Ö: Infantile hemangioma: Efficacy of low-dose propranolol and of
intralesional bleomycin injection for propranolol non-response.
Pediatr Int. 61:459–464. 2019.PubMed/NCBI View Article : Google Scholar
|
21
|
Zhang L, Zheng JW and Yuan WE: Treatment
of alarming head and neck infantile hemangiomas with
interferon-α2a: A clinical study in eleven consecutive patients.
Drug Des Devel Ther. 9:723–727. 2015.PubMed/NCBI View Article : Google Scholar
|
22
|
Soliman YS and Khachemoune A: Infantile
hemangiomas: Our current understanding and treatment options.
Dermatol Online J. 24(13030/qt5jt8q9km)2018.PubMed/NCBI
|
23
|
Léauté-Labrèze C, Dumas de la Roque E,
Hubiche T, Boralevi F, Thambo JB and Taïeb A: Propranolol for
severe hemangiomas of infancy. N Engl J Med. 358:2649–2651.
2008.PubMed/NCBI View Article : Google Scholar
|
24
|
Kado M, Shimizu A, Matsumura T, Mochizuki
M, Mizuno H and Hayashi A: Successful treatment of infantile
hemangiomas with propranolol in low-birth-weight infants. J
Craniofac Surg. 28:789–793. 2017.PubMed/NCBI View Article : Google Scholar
|
25
|
Ainipully AM, Narayanan SK, Vazhiyodan AP
and Somnath P: Oral propranolol in infantile hemangiomas: Analysis
of factors that affect the outcome. J Indian Assoc Pediatr Surg.
24:170–175. 2019.PubMed/NCBI View Article : Google Scholar
|
26
|
Polites SF, Watanabe M, Crafton T, Jenkins
TM, Alvarez-Allende CR, Hammill AM and Dasgupta R: Surgical
resection of infantile hemangiomas following medical treatment with
propranolol vs. corticosteroids. J Pediatr Surg. 54:740–743.
2019.PubMed/NCBI View Article : Google Scholar
|
27
|
Slim K, Nini E, Forestier D, Kwiatkowski
F, Panis Y and Chipponi J: Methodological index for non-randomized
studies (minors): Development and validation of a new instrument.
ANZ J Surg. 73:712–716. 2003.PubMed/NCBI View Article : Google Scholar
|
28
|
Frieden IJ, Haggstrom AN, Drolet BA,
Mancini AJ, Friedlander SF, Boon L, Chamlin SL, Baselga E, Garzon
MC, Nopper AJ, et al: Infantile hemangiomas: Current knowledge,
future directions. Proceedings of a research workshop on infantile
hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA. Pediatr
Dermatol. 22:383–406. 2005.PubMed/NCBI View Article : Google Scholar
|
29
|
Darrow DH: Management of infantile
hemangiomas of the airway. Otolaryngol Clin North Am. 51:133–146.
2018.PubMed/NCBI View Article : Google Scholar
|
30
|
Blei F and Guarini A: Current workup and
therapy of infantile hemangiomas. Clin Dermatol. 32:459–470.
2014.PubMed/NCBI View Article : Google Scholar
|
31
|
Ozeki M, Nozawa A, Hori T, Kanda K, Kimura
T, Kawamoto N and Fukao T: Propranolol for infantile hemangioma:
Effect on plasma vascular endothelial growth factor. Pediatr Int.
58:1130–1135. 2016.PubMed/NCBI View Article : Google Scholar
|
32
|
Khan ZA, Boscolo E, Picard A, Psutka S,
Melero-Martin JM, Bartch TC, Mulliken JB and Bischoff J:
Multipotential stem cells recapitulate human infantile hemangioma
in immunodeficient mice. J Clin Invest. 118:2592–2599.
2008.PubMed/NCBI View
Article : Google Scholar
|
33
|
Greenberger S, Boscolo E, Adini I,
Mulliken JB and Bischoff J: Corticosteroid suppression of VEGF-A in
infantile hemangioma-derived stem cells. N Engl J Med.
362:1005–1013. 2010.PubMed/NCBI View Article : Google Scholar
|
34
|
Matsuda S, Gomi F, Oshima Y, Tohyama M and
Tano Y: Vascular endothelial growth factor reduced and connective
tissue growth factor induced by triamcinolone in ARPE19 cells under
oxidative stress. Invest Ophthalmol Vis Sci. 46:1062–1068.
2005.PubMed/NCBI View Article : Google Scholar
|
35
|
Zhang L, Wu HW, Yuan W and Zheng JW:
Estrogen-mediated hemangioma-derived stem cells through estrogen
receptor-α for infantile hemangioma. Cancer Manag Res. 9:279–286.
2017.PubMed/NCBI View Article : Google Scholar
|
36
|
Liu X, Qu X, Zheng J and Zhang L:
Effectiveness and safety of oral propranolol vs. other treatments
for infantile hemangiomas: A meta-analysis. PLoS One.
10(e0138100)2015.PubMed/NCBI View Article : Google Scholar
|
37
|
Bota M, Popa G, Blag C and Tataru A:
Infantile hemangioma: A brief review. Clujul Med. 88:23–27.
2015.PubMed/NCBI View Article : Google Scholar
|
38
|
Sethuraman G, Yenamandra VK and Gupta V:
Management of infantile hemangiomas: Current trends. J Cutan
Aesthet Surg. 7:75–85. 2014.PubMed/NCBI View Article : Google Scholar
|
39
|
Cavalli R, Buffon RB, de Souza M, Colli AM
and Gelmetti C: Tumor lysis syndrome after propranolol therapy in
ulcerative infantile hemangioma: Rare complication or incidental
finding? Dermatology. 224:106–109. 2012.PubMed/NCBI View Article : Google Scholar
|
40
|
Lee D, Boscolo E, Durham JT, Mulliken JB,
Herman IM and Bischoff J: Propranolol targets the contractility of
infantile haemangioma-derived pericytes. Br J Dermatol.
171:1129–1137. 2014.PubMed/NCBI View Article : Google Scholar
|
41
|
Storch CH and Hoeger PH: Propranolol for
infantile haemangiomas: Insights into the molecular mechanisms of
action. Br J Dermatol. 163:269–274. 2010.PubMed/NCBI View Article : Google Scholar
|
42
|
Pan WK, Li P, Guo ZT, Huang Q and Gao Y:
Propranolol induces regression of hemangioma cells via the
down-regulation of the PI3K/Akt/ eNOS/VEGF pathway. Pediatr Blood
Cancer. 62:1414–1420. 2015.PubMed/NCBI View Article : Google Scholar
|
43
|
de Jong S, Itinteang T, Withers AH, Davis
PF and Tan ST: Does hypoxia play a role in infantile hemangioma?
Arch Dermatol Res. 308:219–227. 2016.PubMed/NCBI View Article : Google Scholar
|
44
|
Sun B, Dong C, Lei H, Gong Y, Li M, Zhang
Y, Zhang H and Sun L: Propranolol inhibits proliferation and
invasion of hemangioma-derived endothelial cells by suppressing the
DLL4/Notch1/Akt pathway. Chem Biol Interact. 294:28–33.
2018.PubMed/NCBI View Article : Google Scholar
|
45
|
Sharifpanah F, Saliu F, Bekhite MM,
Wartenberg M and Sauer H: β-Adrenergic receptor antagonists inhibit
vasculogenesis of embryonic stem cells by downregulation of nitric
oxide generation and interference with VEGF signalling. Cell Tissue
Res. 358:443–452. 2014.PubMed/NCBI View Article : Google Scholar
|
46
|
England RW, Hardy KL, Kitajewski AM, Wong
A, Kitajewski JK, Shawber CJ and Wu JK: Propranolol promotes
accelerated and dysregulated adipogenesis in hemangioma stem cells.
Ann Plast Surg. 73 (Suppl 1):S119–S124. 2014.PubMed/NCBI View Article : Google Scholar
|
47
|
Yao TH, Pataer P, Regmi KP, Gu XW, Li QY,
Du JT, Ge SM and Tu JB: Propranolol induces hemangioma endothelial
cell apoptosis via a p53-BAX mediated pathway. Mol Med Rep.
18:684–694. 2018.PubMed/NCBI View Article : Google Scholar
|
48
|
Yang H, Hu DL, Shu Q and Guo XD: Efficacy
and adverse effects of oral propranolol in infantile hemangioma: A
meta-analysis of comparative studies. World J Pediatr. 15:546–558.
2019.PubMed/NCBI View Article : Google Scholar
|
49
|
Price CJ, Lattouf C, Baum B, McLeod M,
Schachner LA, Duarte AM and Connelly EA: Propranolol vs.
corticosteroids for infantile hemangiomas: A multicenter
retrospective analysis. Arch Dermatol. 147:1371–1376.
2011.PubMed/NCBI View Article : Google Scholar
|
50
|
Lie E and Püttgen KB: Corticosteroids as
an adjunct to propranolol for infantile haemangiomas complicated by
recalcitrant ulceration. Br J Dermatol. 176:1064–1067.
2017.PubMed/NCBI View Article : Google Scholar
|
51
|
Bertrand J, McCuaig C, Dubois J, Hatami A,
Ondrejchak S and Powell J: Propranolol versus prednisone in the
treatment of infantile hemangiomas: a retrospective comparative
study. Pediatr Dermatol. 28:649–654. 2011.PubMed/NCBI View Article : Google Scholar
|
52
|
Rössler J, Schill T, Bähr A, Truckenmüller
W, Noellke P and Niemeyer C: Propranolol for proliferating
infantile haemangioma is superior to corticosteroid therapy-A
retrospective, single centre study. J Eur Acad Dermatol Venereol.
26:1173–1175. 2012.PubMed/NCBI View Article : Google Scholar
|
53
|
Malik MA, Menon P, Rao KLN and Samujh R:
Effect of propranolol vs prednisolone vs propranolol with
prednisolone in the management of infantile hemangioma: a
randomized controlled study. J Pediatr Surg. 48:2453–2459.
2013.PubMed/NCBI View Article : Google Scholar
|
54
|
Bauman NM, McCarter RJ, Guzzetta PC, Shin
JJ, Oh AK, Preciado DA, He J, Greene EA and Puttgen KB: Propranolol
vs prednisolone for symptomatic proliferating infantile
hemangiomas: a randomized clinical trial. JAMA Otolaryngol Head
Neck Surg. 140:323–330. 2014.PubMed/NCBI View Article : Google Scholar
|
55
|
Hoornweg MJ, Saeed P, Tanck MW, Hage JJ,
Coumou AD and Van Der Horst CMAM: Comparison of intralesional
corticosteroid and propranolol treatment of periorbital infantile
hemangiomas: an outcome study of 61 cases. Eur J Ophthalmol.
24:940–947. 2014.PubMed/NCBI View Article : Google Scholar
|
56
|
Kim KH, Choi TH, Choi Y, Park YW, Hong KY,
Kim DY, Choe YS, Lee H, Cheon J-E, Park J, et al: Comparison of
efficacy and safety between propranolol and steroid for infantile
hemangioma: A randomized clinical trial. JAMA Dermatol.
153:529–536. 2017.PubMed/NCBI View Article : Google Scholar
|
57
|
Polites SF, Rodrigue BB, Chute C, Hammill
A and Dasgupta R: Propranolol versus steroids for the treatment of
ulcerated infantile hemangiomas. Pediatr Blood Cancer.
65(e27280)2018.PubMed/NCBI View Article : Google Scholar
|
58
|
Ali A, Aiman U, Haseen MA, Mir MA, Imran
G, Bharadwaj R and Yaseen M: The effect of oral propranolol versus
oral corticosteroids in management of pediatric hemangiomas. World
J Plast Surg. 7:16–24. 2018.PubMed/NCBI
|